Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Rhabdomyosarcoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Central Nervous System Neoplasms 1

Interventions

Radiotherapy 2surufatinib 1sodium thiosulfate 1poly ICLC 1plerixafor 1adavosertib 1Vaccines 1Temozolomide 1Radiation 1Melphalan 1Mannitol 1Irinotecan 1Eflornithine 1Decitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroectodermal Tumors, Primitive × adavosertib × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡